Evidence map›Paper›PMID 38457414›Full record

ArticleJournal of Crohn's & colitis2024

Contrast-Enhanced Endoscopic Ultrasound Detects Early Therapy Response Following Anti-TNF Therapy in Patients with Ulcerative Colitis.

Mark Ellrichmann, Berenice Schulte, Claudio C Conrad, Stephan Schoch, Johannes Bethge, Marcus Seeger, Robert Huber, Madita Goeb, Alexander Arlt, Susanna Nikolaus and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Mark EllrichmannInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID 0000-0002-5817-5589
Berenice SchulteInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Claudio C ConradInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Stephan SchochInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Johannes BethgeInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Marcus SeegerInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Robert HuberInstitute of Biomedical Optics, University of Luebeck, Luebeck, Germany.
Madita GoebDepartment of Internal Medicine, Israelitic Hospital Hamburg, Hamburg, Germany.
Alexander ArltDepartment of Internal Medicine, Israelitic Hospital Hamburg, Hamburg, Germany.
Susanna NikolausInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Christoph RöckenInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID 0000-0002-6989-8002
Stefan SchreiberInterdisciplinary Endoscopy, Medical Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
University Hospital Schleswig-Holstein · DEIsraelitisches Krankenhaus · DEUniversity of Lübeck · DE

Funding

German Research Foundation EXC 2167-390884018
6 · The paper itself

Abstract

BACKGROUND AND

aimsThough colonoscopy plays a crucial role in assessing active ulcerative colitis [aUC], its scope is limited to the mucosal surface. Endoscopic ultrasound [EUS] coupled with contrast-enhancement [dCEUS] can precisely quantify bowel wall thickness and microvascular circulation, potentially enabling the quantitative evaluation of inflammation. We conducted a prospective, longitudinal study to assess therapy response using dCEUS in aUC patients undergoing treatment with adalimumab [ADA] or infliximab [IFX].

methodsThirty ADA- and 15 IFX-treated aUC patients were examined at baseline and at 2, 6, and 14 weeks of therapy and 48 weeks of follow-up. Bowel wall thickness [BWT] was measured by EUS in the rectum. Vascularity was quantified by dCEUS using rise time [RT] and time to peak [TTP]. Therapy response was defined after 14 weeks using the Mayo Score.

resultsPatients with aUC displayed a mean BWT of 3.9 ± 0.9 mm. In case of response to ADA/IFX a significant reduction in BWT was observed after 2 weeks [p = 0.04], whereas non-responders displayed no significant changes. The TTP was notably accelerated at baseline and significantly normalized by week 2 in responders [p = 0.001], while non-responders exhibited no significant alterations [p = 0.9]. At week 2, the endoscopic Mayo score did not exhibit any changes, thus failing to predict treatment responses.

conclusiondCEUS enables the early detection of therapy response in patients with aUC, which serves as a predictive marker for long-term clinical success. Therefore, dCEUS serves as a diagnostic tool for assessing the probability of future therapy success.

Indexed as

AdalimumabColitis, UlcerativeContrast MediaEndosonographyInfliximabAdultFemaleGastrointestinal AgentsHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesTreatment OutcomeTumor Necrosis Factor-alphaAdalimumabContrast MediaGastrointestinal AgentsInfliximabTumor Necrosis Factor-alphabiological therapyendoscopic ultrasoundUlcerative colitis

Identifiers

PMID38457414
PMCPMC11302966
OpenAlexW4392582562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.